CTVP regimen in the treatment for non-Hodgkin's lymphoma

Yun Hou, Huaqing Wang, Huilai Zhang, Zhengzi Qian, Shiyong Zhou, Lihua Qiu, Kai Fu, Xianming Liu, Xiuzhen Cui

Research output: Contribution to journalArticlepeer-review


Objective: To analyze the efficacy and toxicity of the CTVP regimen in the treatment of non-Hodgkin's lymphoma (NHL). Methods: From January 2000 to December 2005, 85 patients with NHL were treated with the CTVP regimen with or without radiotherapy for the involved field. The clinical characteristics, response, toxicity, and long-term survival results were analyzed retrospectively. Results: Of the 85 patients, 74 received initial treatment, 11 were treated again. A total of 85 patients were eligible. The clinical benefit rate of the first-line therapy was 86.0%, the response rate was 68.9%, and the complete response rate was 55.4%. The clinical benefit rate of the second-line therapy was 63.6%; the response rate was 45.5%. The median follow-up duration in this series was 69 months (range: 6-102 months). The overall 1-, 3-, 5-year survival rates were 82.4%, 71.5%, and 60.7%, respectively, with a median survival time of 75 months (6-99). The major toxic effects of the regimen were myelosuppression, GI toxicity, fatigue, neurotoxicity, and alopecia. Conclusion: The CTVP regimen is effective and well tolerated by the non-Hodgkin's lymphoma patients.

Original languageEnglish (US)
Pages (from-to)1099-1102
Number of pages4
JournalChinese Journal of Clinical Oncology
Issue number18
StatePublished - Sep 30 2011


  • Non-Hodgkin's lymphoma
  • Overall survival
  • Pirarubicin
  • Vindesine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'CTVP regimen in the treatment for non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this